Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Clinical trial NCT02103478 · COMPLETED
Trial details
- NCT number
- NCT02103478
- Sponsor
- Astex Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-28
- Primary completion
- 2018-06-05
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.